Search the Newsreel

AC Immune Secures FDA Fast Track For ACI-7104 In Parkinson's; Stock Up

(RTTNews) - AC Immune SA (ACIU) announced that the FDA has granted Fast Track designation to ACI-7104, its anti-alpha-synuclein active immunotherapy for the treatment of early Parkinson's disease. Parkinson's disease is a progressive neurodegenerative disorder affecting movement and quality of life. Alpha-synuclein proteins are …

AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)

AC Immune SA announced that its anti-alpha-synuclein active immunotherapy candidate, ACI-7104, has received FDA Fast Track designation and IND clearance for treating early Parkinson's disease (PD). The designation acknowledges the potential of ACI-7104 to address significant unmet needs in PD, based on positive interim …

AC Immune’s Parkinson’s Candidate Shows 100% Responder Rate

AC Immune (NASDAQ: ACIU) has received FDA Fast Track designation and IND clearance for ACI-7104, its anti-alpha-synuclein active immunotherapy, to treat early Parkinson’s disease. Interim Phase 2 data at 76 weeks showed ACI-7104 was safe, well-tolerated, and achieved a 100% immunogenicity responder rate. The …

AC Immune (NASDAQ: ACIU) gains FDA Fast Track, IND clearance for Parkinson’s drug ACI-7104

AC Immune (NASDAQ: ACIU) announced that its anti-alpha-synuclein active immunotherapy, ACI-7104, received FDA Fast Track designation and IND clearance for early-stage Parkinson’s disease. This designation facilitates development and regulatory review for ACI-7104, which showed promising interim Phase 2 results for safety, tolerability, and immunogenicity. …

AC Immune receives FDA fast track status for parkinson’s drug

AC Immune SA announced that the FDA granted Fast Track designation and cleared its Investigational New Drug application for ACI-7104, an anti-alpha-synuclein active immunotherapy for early-stage Parkinson’s disease. This designation is based on positive interim Phase 2 data from the VacSYn trial, showing the …

AC Immune SA Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

AC Immune SA reported a significant earnings miss for its latest quarter, with revenues of CHF15m and EPS of CHF0.02 falling short of analyst expectations. Following these results, analysts have revised their forecasts, increasing revenue estimates for 2026 to CHF45.7m but also projecting higher …

AC Immune earnings missed by CHF0.18, revenue fell short of estimates

AC Immune (NasdaqGM:ACIU) Stock Price Shrugs Off Surprise Quarterly Profit

AC Immune (NasdaqGM:ACIU) reported a surprise Q2 2026 profit with basic earnings per share of 0.018701 CHF and revenue of 15.113m CHF, a significant turnaround from a loss in the previous year. Despite this positive financial shift for the Alzheimer and neurodegeneration specialist, the …

BTIG Research Reaffirms "Buy" Rating for AC Immune (NASDAQ:ACIU)

AC Immune (NASDAQ:ACIU) Announces Earnings Results, Misses Estimates By $0.09 EPS

AC Immune Files First-Half 2026 Results and Corporate Update on Form 6-K

AC Immune First Half 2026 Financial and Corporate Update Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments Key advances across pipeline, with further near-term clinical results anticipated for H2 2026Phase 2 VacSYn trial of ACI-7104 in Parkinson’s …

AC Immune: Q2 Earnings Snapshot

AC Immune’s Parkinson’s Trial Gets a $4 Million Grant

AC Immune (NASDAQ: ACIU) reported its first-half 2026 financial and corporate update, highlighting a $4 million grant for its Phase 2 VacSYn trial (ACI-7104) for Parkinson’s disease. The company also received a $12 million milestone payment from Takeda for initiating a new cohort in …

Partner milestones lift AC Immune (NASDAQ: ACIU) cash and cut loss

AC Immune (ACIU) Beats Q2 Earnings and Revenue Estimates

AC Immune SA Revenue Breakdown – HAM:IMR

AC Immune SA generated €3.84 million in revenue last year, primarily from its Therapeutic and Diagnostic Products segment, which contributed €3.66 million. This is a significant decrease from the previous year's €29.95 million. The majority of this revenue, €3.66 million, originated from Switzerland.

AC Immune SA (ACIU) Financial Health: Profitability & Balance Sheet Analysis

AC Immune SA (ACIU) has a weak financial status and low operating efficiency, ranking 351 out of 384 in the Biotechnology & Medical Research industry with a financial score of 5.50. Despite this, its latest quarterly revenue increased by 19.51% year-over-year to $1.43 million, …

AC Immune SA (ACIU) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for AC Immune SA (ACIU), noting its current risk score of 1.90 and ranking within the Biotechnology & Medical Research industry. It details the company's beta value of 1.61, indicating higher volatility compared to the S&P 500, and …

AC Immune (ACIU) Expected to Announce Quarterly Earnings on Tuesday

AC Immune SA (ACIU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey attempts to provide a revenue breakdown for AC Immune SA (ACIU), covering business segments and regional contributions. However, it explicitly states that the relevant data for these categories has not been disclosed by the company. Therefore, the content primarily highlights …

ACIU|AC Immune SA|Price:2.230|Chg%:-0.010

AC Immune SA (ACIU) is a clinical-stage biopharmaceutical company focusing on neurodegenerative diseases. The stock is currently priced at $2.230, down 0.45%, and holds a "Strong Buy" rating from analysts with a target price of $8.60. Despite recent weak stock market performance, its fundamentals …

AC Immune SA Revenue Breakdown – TRADEGATE:IMR

AC Immune SA reported its revenue breakdown for the last year, with total revenue reaching 3.84 million EUR. The primary segment contributing to this revenue was Therapeutic and Diagnostic Products, generating 3.66 million EUR, a significant decrease from 29.95 million EUR in the prior …